Development of Diagnostics and Treatment of Urological Cancers
Who is this study for? Adults with urological cancers
What treatments are being studied? Personalised treatment
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
The purpose of the study is to evaluate whether state-of-the-art technologies such and next generation sequencing and drug sensitivity and resistance testing of patient derived tumour tissue can facilitate research translation and improve outcome of urologic cancers.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• The patient is able to provide written informed consent and is at least 18 years of age
• The patient must have a verified diagnosis of an urologic cancer by a board-certified clinician
Locations
Other Locations
Finland
Helsinki University Hospital
RECRUITING
Helsinki
Contact Information
Primary
Antti S Rannikko, MD, PhD
antti.rannikko@hus.fi
+35894711
Time Frame
Start Date: 2017-11-27
Estimated Completion Date: 2025-12
Participants
Target number of participants: 100
Treatments
Other: Personalised medicine arm
This is a prospective n-of-1 type of trial where every patient is his/her own control. This is a study further developing the translational use of an existing framework and infrastructure for systematic sample collection an analytics previously established in the HUB project incorporating NGS and DSRT into clinical care.
Related Therapeutic Areas
Sponsors
Collaborators: Karolinska Institutet
Leads: Helsinki University Central Hospital